Liquidia Corporation LQDA R2KR3KPHARMA
Company Overview
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Why Investors Should Care
Generates a return on equity of 28.2%, reflecting efficient use of shareholder capital.
Revenue has grown at a 81.3% CAGR over the past five years.
Operating margin of 46.3% supports profitability.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $158.32M (+1031.2% YoY); net profit $-68.92M.
- Trailing 12 Months Year-on-year growth — revenue +4158.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 81.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 81.35% |
| 1 Year: | 4,158.50% |
Stock Price Performance
| 1 Year: | +172.46% |
| 6 Months: | +90.56% |
| 3 Months: | +11.01% |
| 1 Month: | -23.22% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)39.96 · Neutral
P/E of 403.88 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 28.2%.
- Compounding revenue at 81.3% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 403.9.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LQDA Liquidia Corporation R2KR3KPHARMA | 68.66 | 403.88 | $6.11B | 0.00% | -26.74% | 28.18% | 81.35% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 3.08M | 3.38M | 3.18M | 3.49M | 3.92M | 3.17M | 4.49M | 4.79M | 3.68M | 2.97M | 3.66M | 4.45M | - | 3.12M | 8.84M | 54.34M | 92.02M | 132.87M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.52M | 1.50M | 3.17M | 7.05M | 11.85M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.60M | 7.34M | 51.17M | 84.97M | 121.01M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 37.03M | 44.84M | 49.40M | 65.18M | 59.51M |
| Operating Income | -14.65M | -13.72M | -14.81M | -9.00M | -6.35M | -7.08M | -14.47M | -8.97M | -8.83M | -9.23M | -22.82M | -14.89M | -28.80M | -27.20M | -29.19M | - | -35.42M | -37.51M | 1.77M | 19.79M | 61.50M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -33.25M | -35.64M | 3.89M | 21.77M | 63.77M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.67M | 5.66M | 6.95M | 6.90M | 6.49M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -38.37M | -41.58M | -3.53M | 14.55M | 56.78M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | 3.92M |
| Net Income | -14.79M | -13.92M | -14.97M | -9.18M | -6.55M | -7.28M | -15.94M | -9.45M | -9.09M | -11.74M | -23.52M | -15.79M | -30.08M | -28.67M | -31.03M | - | -38.37M | -41.58M | -3.53M | 14.55M | 52.86M |
| Diluted EPS | - | - | - | -0.21 | -0.13 | -0.14 | -0.30 | -0.15 | -0.14 | -0.18 | -0.36 | -0.24 | -0.40 | -0.38 | -0.40 | - | -0.45 | -0.49 | -0.04 | 0.15 | 0.52 |
| R&D Expense | 10.82M | 8.49M | 7.66M | 6.05M | 4.59M | 4.49M | 4.73M | 5.22M | 4.51M | 5.28M | 17.70M | 7.44M | 10.06M | 9.42M | 11.89M | - | 6.97M | 6.02M | 9.35M | - | 12.57M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 8.07M | 739.63K | - | 15.94M | 17.49M | 14.00M | 158.32M |
| Cost of Revenue | - | - | - | 2.86M | 2.89M | 5.88M | 13.24M |
| Gross Profit | - | - | - | 13.08M | 14.60M | 8.12M | 145.08M |
| Operating Expenses | - | - | - | 51.85M | 87.98M | 129.41M | 196.45M |
| Operating Income | -46.82M | -59.09M | - | -38.77M | -73.38M | -121.29M | -51.38M |
| EBITDA | - | - | - | -35.03M | -70.05M | -111.44M | -43.22M |
| Interest Expense | - | - | - | 2.34M | 6.27M | 14.65M | 24.17M |
| Pretax Income | - | - | - | -41.02M | -78.50M | -128.29M | -68.92M |
| Tax Provision | - | - | - | - | - | - | - |
| Net Income | -47.58M | -59.76M | - | -41.02M | -78.50M | -128.29M | -68.92M |
| Diluted EPS | -2.57 | -1.76 | - | -0.67 | -1.21 | -1.66 | -0.80 |
| R&D Expense | 40.49M | 32.22M | 20.52M | 19.43M | 43.24M | 47.84M | 39.28M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 68.84M | 99.53M | - | 129.20M | 118.33M | 230.31M | 327.93M |
| Current Assets | - | - | - | - | 99.81M | 89.90M | 185.10M | 273.40M |
| Cash & Equivalents | - | - | 65.32M | - | 93.28M | 83.68M | 176.48M | 190.68M |
| Inventory | - | - | - | - | - | 0 | 241.00K | 23.80M |
| Receivables | - | - | - | - | 5.02M | 4.06M | 2.72M | 54.09M |
| Total Liabilities | - | 33.89M | 28.45M | - | 38.78M | 71.04M | 150.94M | 283.19M |
| Current Liabilities | - | 16.87M | 11.74M | - | 8.80M | 18.55M | 41.78M | 135.77M |
| Long Term Debt | - | 10.29M | 10.29M | - | 19.88M | 43.42M | 95.27M | 132.94M |
| Total Debt | - | - | - | - | 24.46M | 49.54M | 120.29M | 197.93M |
| Total Equity | 18.69M | 34.95M | 71.09M | - | 90.42M | 47.29M | 79.38M | 44.75M |
| Shares Outstanding | - | - | - | - | 64.52M | 68.63M | 84.68M | 87.20M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -48.28M | -54.14M | -34.03M | -28.59M | -41.56M | -93.42M | -35.69M |
| Investing Cash Flow | -1.85M | 247.91K | -107.00K | -587.00K | -11.29M | -8.44M | -6.34M |
| Financing Cash Flow | 66.39M | 63.42M | 26.32M | 64.96M | 43.25M | 194.66M | 59.73M |
| Capital Expenditure | -1.85M | -752.09K | -107.00K | -592.00K | -1.29M | -4.95M | -4.34M |
| Free Cash Flow | -50.13M | -54.90M | -34.14M | -29.18M | -42.85M | -98.37M | -40.02M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 82.1% | 83.5% | 58.0% | 91.6% |
| Operating Margin % | -580.1% | -7,989.0% | - | -243.3% | -419.6% | -866.6% | -32.5% |
| Net Margin % | -589.5% | -8,080.1% | - | -257.4% | -448.9% | -916.6% | -43.5% |
| ROE % | -136.2% | -84.1% | - | -45.4% | -166.0% | -161.6% | -154.0% |
| ROCE % | -90.1% | -67.3% | - | -32.2% | -73.5% | -64.3% | -26.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 12.05% | 10.79M | $730.28M |
| 2 | Farallon Capital Management LLC | 9.35% | 8.37M | $566.23M |
| 3 | Caligan Partners, LP | 9.07% | 8.12M | $549.57M |
| 4 | Findell Capital Management LLC | 3.91% | 3.50M | $237.06M |
| 5 | Vanguard Capital Management LLC | 3.51% | 3.14M | $212.49M |
| 6 | State Street Corporation | 3.39% | 3.03M | $205.13M |
| 7 | Opaleye Management Inc. | 2.73% | 2.45M | $165.67M |
| 8 | Geode Capital Management, LLC | 2.37% | 2.12M | $143.59M |
| 9 | Bank of America Corporation | 2.22% | 1.99M | $134.81M |
| 10 | Price (T.Rowe) Associates Inc | 2.17% | 1.94M | $131.34M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LQDA
Liquidia (LQDA) Stock Looks Stretched On Earnings But Reasonable On Broader Checks - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOWDdmT3ZwX18tZ2ZDVWJKRFhDVjU5UGpibVUyQXBpYTZsSGJfbGJRM2FvTm1kaHVmd2g3R181NmtyU2IzSFZBX1dSLXFyTTU0alcwb0pGOHBlajdPUVR3VW15Tlk4UE9kUnRFSTFaaFgzbGx1ZTBORk9SVkx6eVNQemIzdWo5b2E1WjJuWE…
Liquidia (LQDA) Could Be 4% Undervalued Following New Pulmonary Hypertension Data - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxOMTZEU0NNNExnUS1QSmxZOGZlQ3VxMzVTZVZTMkUwMldKY3ZZbnVkYXVTUnVWVUM2SlZjUHlodlEzbVh5RV85bmI3UDBxNjJDNUdfWHQ5eXhWcTVUVmZkSkNWbGRQSFJlNU1yYjk2RXd6c2x0c18wS00zLU5zWmlJWlU1SXM3WXNfaFJZUz…
Liquidia Gets FDA Fast Track for YUTREPIA Raynaud's | LQDA Stock News - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOWHdUVWp6OVRmT0NxNjlzZThMbWF2Y1gwWjNUU0dwWkU2ZE9FUGdlOVVWTkZ0aUZaZkVSSElXWFFkT3lJUk5HNXl5V1Vmd29PYUdHQmNCem1LV0pBUEU3TEh4emZFVHdmZEMwR0NhRFZVVjd3WjRQWk5VbW15bHgzMzNiWl9vZXZvOXlHdW…
Liquidia Corporation $LQDA Shares Sold by Pale Fire Capital SE - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQcEtFQXBtR1lIcE1RaDdDdThZNDFLVmd4X1JsUmY3OW15U2dLRFFGT3UzZEd2X3p6YTBfdGdXeHlYaDZHaGpzVUdfeG9SQmdiTFRwZjlLWV92YVdkNHAwZ2xsTmVvaV84dVJnNnlUTlVoR2dvZGktQUFjUGdQWHJURDVJSW50SnlRaU5Ucz…
Why Is Liquidia Stock Gaining Thursday? - Liquidia (NASDAQ:LQDA) - Benzinga
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOMDV3UEp3V3FELTVlak1LN3lPS3ctS2lZalVVWG90dGJhSjB3dGhyclB3SHB2TDdDVjBLejNBRm5SOUVzTF9VRVdqQkNuUlZFRFQ4OEh5OGk5Y0RLVlBJNENYZnowQ1VWdlFOWHY3YUFvZUpuRmdGOWFKLWtSVXZla3dONTc3OEtXaUxsSG…
LQDA Stock Down Post Q2 Earnings Release: What Should Investors Do Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNanZnbUJtcW9NamMwalBRUXBRN1FlU0pfS0ExZEhCcE5lXzlKZmh2REpjbm01ZC1NYTdRMndXUEJoOVZmZlNNMlZ6SXhGQU00UVR5djJ6NTJKM2o3YTAzcDhJV3BxRFBES09mYTQtdXhQOW9BX0tVM2ZiSm1kZkxRLTJDWkFQNUhweWtrd1…
LQDA — Frequently Asked Questions
What is the current share price of Liquidia Corporation (LQDA)?
As of 2026-09-07 16:24 PDT, Liquidia Corporation (LQDA) trades at $68.66 on NasdaqCM. Its 52-week range is $21.80 to $91.03.
What is the market capitalisation of LQDA?
Liquidia Corporation (LQDA) has a market capitalisation of $6.11B on NasdaqCM.
What is the P/E ratio of LQDA?
LQDA trades at a trailing price-to-earnings (P/E) ratio of 403.88. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 73.35.
What is the return on equity (ROE) of LQDA?
LQDA has a return on equity (ROE) of 28.18%. Its return on capital employed (ROCE) is -26.74%.
Is LQDA a good stock to buy?
This page provides a data-driven analysis of Liquidia Corporation (LQDA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.